News
Clinical Trials Arena on MSN16h
FDA clears Caliway’s trial of CBL-514 for localised fat reductionThe top-line outcomes from SUPREME-01 are anticipated between the fourth quarter of 2026 and the first quarter of 2027.
Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...
Health and Me on MSN23h
Demand For Weight Loss Injections Now ‘Unsustainable’, Experts Say Most Don’t QualifyExperts warn that the surge in demand for weight loss injections like Ozempic and Wegovy is unsustainable, with most users ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback